Kevin G Peters

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11107283/publications.pdf

Version: 2024-02-01

40 papers	3,406 citations	159585 30 h-index	315739 38 g-index
40 all docs	40 docs citations	40 times ranked	3782 citing authors

#	Article	IF	Citations
1	Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension. Translational Vision Science and Technology, 2022, 11, 7.	2.2	7
2	VE-PTP inhibition elicits eNOS phosphorylation to blunt endothelial dysfunction and hypertension in diabetes. Cardiovascular Research, 2021, 117, 1546-1556.	3.8	33
3	Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19. JCI Insight, 2021, 6, .	5.0	35
4	A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure. , 2020, 61, 12.		25
5	Controversial roles for dexamethasone in glioblastoma â€“ Opportunities for novel vascular targeting therapies. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1460-1468.	4.3	33
6	Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1298-1303.	7.1	85
7	Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema. Current Diabetes Reports, 2016, 16, 126.	4.2	71
8	Angiopoietin-2-induced bloodâ€“brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling. Acta Neuropathologica, 2016, 131, 753-773.	7.7	120
9	Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. Journal of Clinical Investigation, 2014, 124, 4564-4576.	8.2	174
10	Engineering the catalytic domain of human protein tyrosine phosphatase Î² for structure-based drug discovery. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 1435-1445.	2.5	23
11	Design and synthesis of potent, non-peptidic inhibitors of HPTPÎ². Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4252-4256.	2.2	31
12	1,2,3,4-Tetrahydroisoquinolinyl sulfamic acids as phosphatase PTP1B inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1574-1578.	2.2	78
13	Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: Support for an endothelium-dependent mechanism. Cardiovascular Research, 2006, 69, 925-935.	3.8	50
14	A Nonspecific Phosphotyrosine Phosphatase Inhibitor, Bis(maltolato)oxovanadium(IV), Improves Glucose Tolerance and Prevents Diabetes in Zucker Diabetic Fatty Rats. Experimental Biology and Medicine, 2005, 230, 207-216.	2.4	43
15	Tyrosine phosphatases in vessel wall signaling. Cardiovascular Research, 2005, 65, 587-598.	3.8	63
16	Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H268-H276.	3.2	32
17	Functional Significance of Tie2 Signaling in the Adult Vasculature. Endocrine Reviews, 2004, 59, 51-71.	6.7	150
18	Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. Journal of Inorganic Biochemistry, 2003, 96, 321-330.	3.5	127

#	Article	IF	Citations
19	Proteome analysis of the rat cornea during angiogenesis. Proteomics, 2003, 3, 2258-2266.	2.2	26
20	Neovascularization in intimal hyperplasia is associated with vein graft failure after coronary artery bypass surgery. Vascular Medicine, 2003, 8, 163-167.	1.5	9
21	Deletion of the Carboxyl Terminus of Tie2 Enhances Kinase Activity, Signaling, and Function. Journal of Biological Chemistry, 2002, 277, 31768-31773.	3.4	50
22	The Endothelial Receptor Tyrosine Kinase Tie1 Activates Phosphatidylinositol 3-Kinase and Akt To Inhibit Apoptosis. Molecular and Cellular Biology, 2002, 22, 1704-1713.	2.3	91
23	1H, 15N, and 13C resonance assignments of low molecular weight human cytoplasmic protein tyrosine phosphatase-A (HCPTP-A). Journal of Biomolecular NMR, 2002, 23, 251-252.	2.8	3
24	Systemically Expressed Soluble Tie2 Inhibits Intraocular Neovascularization. Human Gene Therapy, 2001, 12, 1311-1321.	2.7	67
25	HCPTPA, a Protein Tyrosine Phosphatase That Regulates Vascular Endothelial Growth Factor Receptor-mediated Signal Transduction and Biological Activity. Journal of Biological Chemistry, 1999, 274, 38183-38188.	3.4	79
26	VEGF enhances pulmonary vasculogenesis and disrupts lung morphogenesis in vivo. , 1998, 211, 215-227.		179
27	Isolation of the zebrafish homologues for thetie-1 andtie-2 endothelium-specific receptor tyrosine kinases. Developmental Dynamics, 1998, 212, 133-140.	1.8	101
28	Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia. Annals of Thoracic Surgery, 1998, 66, 2029-2036.	1.3	89
29	Neovascularization in atherectomy specimens from patients with unstable angina: Implications for pathogenesis of unstable angina. American Heart Journal, 1998, 135, 10-14.	2.7	162
30	Tyrosine 1101 of Tie2 Is the Major Site of Association of p85 and Is Required for Activation of Phosphatidylinositol 3-Kinase and Akt. Molecular and Cellular Biology, 1998, 18, 4131-4140.	2.3	202
31	Induction and maintenance of increased VEGF protein by chronic motor nerve stimulation in skeletal muscle. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 274, H860-H867.	3.2	73
32	Isolation of the zebrafish homologues for the tie1 and tie2 endotheliumâ€specific receptor tyrosine kinases. Developmental Dynamics, 1998, 212, 133-140.	1.8	4
33	Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels. Cardiovascular Research, 1997, 35, 505-513.	3.8	36
34	Tie2 Expression and Phosphorylation in Angiogenic and Quiescent Adult Tissues. Circulation Research, 1997, 81, 567-574.	4.5	354
35	PDGF and FGF receptors in health and disease. Growth Factors and Cytokines in Health and Disease, 1996, , 179-228.	0.2	3
36	Collagen Subtypes III and IV Expression in Human Vein Graft Atherosclerosis. American Journal of Cardiology, 1996, 78, 691-694.	1.6	3

#	Article	IF	Citations
37	Green Fluorescent Fusion Proteins: Powerful Tools for Monitoring Protein Expression in Live Zebrafish Embryos. Developmental Biology, 1995, 171, 252-257.	2.0	68
38	Differential Expression of Tissue Factor Protein in Directional Atherectomy Specimens From Patients With Stable and Unstable Coronary Syndromes. Circulation, 1995, 91, 619-622.	1.6	200
39	Phospholipase CÎ³ Activation, Phosphotidylinositol Hydrolysis, and Calcium Mobilization are Not Required for FGF Receptor-Mediated Chemotaxis. Cell Adhesion and Communication, 1994, 1, 333-342.	1.7	34
40	Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis. Nature, 1992, 358, 678-681.	27.8	393